Healthcare / Pharmaceutical RetailersThailand
$5.85
-0.05 (-0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $10.3M · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
20.9x
↑EV/EBITDA
9.0x
↓ROE
8.0%
↑Gross Margin
24.3%
↓Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
+117.6%
FCF margin
7.2%
FCF / Net income
2.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.23B · net income $77.9M · FCF $160.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.23B | $2.23B | $1.98B | $1.64B | $1.52B |
| Net Income | $77.9M | $77.9M | $78.3M | $74.7M | $118.2M |
| EBITDA | $207.8M | $207.8M | $187.2M | $159.0M | $186.7M |
| EPS | — | — | 0.29 | 0.27 | 0.43 |
| Gross Margin | 24.3% | 24.3% | 23.5% | 23.1% | 24.8% |
| Operating Margin | 5.0% | 5.0% | 4.8% | 6.2% | 9.8% |
| Net Margin | 3.5% | 3.5% | 4.0% | 4.6% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.29 | 0.23 | 0.18 |
| Current Ratio | 3.03 | 3.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $160.0M | $160.0M | $10.3M | $8.4M | $15.5M |
| Returns | |||||
| ROE | 8.0% | 8.0% | 7.8% | 7.7% | 12.6% |
| Valuation | |||||
| P/E | 20.89 | 20.89 | 35.52 | 39.63 | 57.91 |
| EV/EBITDA | 8.96 | 8.96 | 15.65 | 17.60 | 36.40 |
| P/B | 1.63 | 1.63 | 2.79 | 3.01 | 7.19 |
| Growth & Yield | |||||
| Revenue Growth | 12.7% | 12.7% | 20.9% | 7.6% | — |
| EPS Growth | — | — | 7.4% | -37.2% | — |
| Dividend Yield | 3.8% | 3.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.29 → n/d
Residual
-7.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.